.

Biocryst Pharmaceuticals reported $81.02M in Current Liabilities for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
DBV Technologies DBVT:US 30.43M 4.4M
Alnylam Pharmaceuticals ALNY:US $ 657.68M 51.72M
Chemocentryx CCXI:US $ 76.08M 7.27M
Chugai Pharma 4519:JP Y 294442M 26073M
Daiichi Sankyo 4568:JP Y 406816M 11548M
Enanta Pharmaceuticals ENTA:US $ 23.04M 7.7M
Gilead Sciences GILD:US $ 9220M 662M
GlaxoSmithKline GSK:LN 3783500M 1355700M
Glaxosmithkline GSK:US $ 37835M 13557M
Intra Cellular Therapies ITCI:US $ 70.63M 11.56M
IONIS PHARMACEUT IONS:US $ 267.81M 39.36M
Karyopharm Therapeutics KPTI:US $ 62.54M 3.8M
Mirati Therapeutics MRTX:US $ 119.15M 4.42M
Neurocrine Biosciences NBIX:US $ 285.7M 32.2M
Novavax NVAX:US $ 2156.24M 104.77M
Ptc Therapeutics PTCT:US $ 567.37M 90.6M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M
Sarepta Therapeutics SRPT:US $ 545.57M 90.6M
Ultragenyx Pharmaceutical RARE:US $ 220.64M 53.4M
Vertex Pharmaceuticals VRTX:US $ 2556.2M 376M
YTE INCY:US $ 926.67M 40.51M